Asambly Chemicals Co. Ltd.

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
News
Home ProductsActive Pharmaceutical Ingredients

Silodosin KAD - 3213 Active Pharmaceutical Ingredients , KMD - 3213 CAS 160970 54 7 GMP DMF

I'm Online Chat Now

Silodosin KAD - 3213 Active Pharmaceutical Ingredients , KMD - 3213 CAS 160970 54 7 GMP DMF

China Silodosin KAD - 3213 Active Pharmaceutical Ingredients  , KMD - 3213 CAS 160970 54 7 GMP DMF supplier

Large Image :  Silodosin KAD - 3213 Active Pharmaceutical Ingredients , KMD - 3213 CAS 160970 54 7 GMP DMF

Product Details:

Place of Origin: CHINA
Certification: GMP condition

Payment & Shipping Terms:

Minimum Order Quantity: 1KG
Packaging Details: Drum
Contact Now
Detailed Product Description
Name: Silodosin Synonyms: KAD - 3213 , KMD - 3213
CAS: 160970-54-7 Molecular Formula: C25H32F3N3O4
High Light:

274693 27 5

,

1377049 84 7

Silodosin , KAD - 3213 , KMD - 3213 CAS : 160970-54-7 GMP DMF

 

Name : Silodosin

 

CAS No . : 160970-54-7

 

Synonyms :  KAD - 3213 , KMD - 3213

 

Chemical Name : 1 - ( 3 - hydroxypropyl ) - 5 - [ ( 2) - ( { 2 - [ 2 - [ 2 - ( 2 , 2 , 2 - trifluoroethoxy ) phenoxy ] ethyl } } amino ) propyl ] indoline - 7 - carboxamide

 

Molecular Formula : C25H32F3N3O4

 

Molecular Weight : 495.53

 

Description : 

 

Silodosin is an active pharmaceutical ingredient ( API ) used for the symptomatic treatment of benign prostatic hyperplasia - BPH acting as alpha1-adrenoceptor antagonist with high selectivity of prostate. It does not shrink the prostate but relax the muscles in the prostate and bladder.

 

It is first approved in Japan in May 2006 under the brand name Urief, which is jointly marketed by Daiichi Sankyo Pharmaceutical Co., Ltd and Kissei Pharmaceutical Co., Ltd. The US, Canada and Mexico rights were lincensed to Watson Pharmaceutical Co., Ltd by Kissei Pharmaceutical in 2004 and Silodosin was approved by FDA in Oct 9, 2008. Silodosin has many trade names, Rapaflo in USA, Silodyx in Europe and South Africa, Rapilif, Silodal or Sildoo in India, Urief in Japan, Thrupas in South Korea, Urorec in Russia and so on.

 

The drug might be protected by patents in some courtires or areas. We only sell it to non patent protected countries or areas. The sale to patent protection countries and areas is only for R & D purpose. The buyers should take all responsiblity of patent status in his countries or areas.

 

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.

 

Contact Details
Asambly Chemicals Co. Ltd.

Contact Person: MAO Xiaolong

Send your inquiry directly to us (0 / 3000)